BeyondSpring, Inc. - Ordinary Shares (BYSI) analyst actions
Rating and price-target actions on BYSI in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the BYSI overview →
1 measured BYSI analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer | Press release | -0.79% | +11.22% |
Keep exploring
More BYSI: earnings → · SEC filings → · BYSI overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| INMED PHARMACEUTICALS (IMLFF) | 148 | 0.00% | 48% |
| Akari Therapeutics Plc - American Depositary Shares (AKTX) | 146 | 0.00% | 45% |
| Clearside Biomedical, Inc. (CLSD) | 145 | 0.00% | 46% |
| Oramed Pharmaceuticals Inc. (ORMP) | 145 | +0.69% | 69% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.